Abstract
Current literature on the cardioprotective effects of agents targeted against the renin-angiotensin-aldosterone system (RAAS) in trastuzumab (TRA)-treated human epidermal receptor (HER2) positive breast cancer patients is conflicting. We hypothesized that concurrent use of anti-RAAS agents would
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
